Showing results (101-110 of 370) with videos related to
Sort By:
Pageof 37
Human Molecular Genetics|March 2, 2012
NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosisHylke M Blauw, Wouter van Rheenen, Max Koppers, et al.Neurobiology of Disease|August 24, 2013
Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) miceKim A Staats, Lawrence Van Helleputte, Ashley R Jones, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 17, 2008
Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degenerationKoen Poesen, Diether Lambrechts, Philip Van Damme, et al.Studies in Health Technology and Informatics|November 19, 2021
FAIRification Efforts of Clinical Researchers: The Current State of AffairsMartijn G Kersloot, Philip van Damme, Ameen Abu-Hanna, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 25, 2023
Prognostic value of motor and extramotor involvement in ALSVincent Kabir, Fouke Ombelet, Frederik Hobin, et al.European Journal of Neurology|March 9, 2021
Neuropathy of the phrenic nerve associated with antiganglioside antibodiesAnouk Serrien, Katrien Sanders, Kristl G Claeys, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 19, 2024
Specialized multidisciplinary care improves ALS survival in Belgium: a population-based retrospective studyFrederik Hobin, Joke De Vocht, Nikita Lamaire, et al.Journal of the American Medical Informatics Association : JAMIA|January 23, 2023
MIMIC-IV on FHIR: converting a decade of in-patient data into an exchangeable, interoperable formatAlex M Bennett, Hannes Ulrich, Philip van Damme, et al.European Journal of Human Genetics : EJHG|March 26, 2009
Variant on 9p21 strongly associates with coronary heart disease, but lacks association with common strokeRobin Lemmens, Shérine Abboud, Wim Robberecht, et al.Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 20, 2009
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trialVincent Meininger, Vivian E Drory, P Nigel Leigh, et al.Pageof 37